NASDAQ: SGEN       Seattle Genetics Inc
Last Price Today's Change   Day's Range   Trading Volume
109.52   -4.05 (3.57%)  109.405 - 112.48  433,003


Avg Volume (4 weeks):973,616
4 Weeks Range:104.24 - 118.655
4 Weeks Price Volatility (%):
52 Weeks Range:62.90 - 122.36
52 Weeks Price Volatility (%):
Average Price Target: 49.20
Price Target Upside/Downside: -60.32


No recent Headlines for this stock.

Business Background

Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company's marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC). In addition to ADCETRIS, the Company's pipeline includes other clinical-stage ADC programs, such as ASG-22ME, SGN-LIV1A, SGN-CD19A, SGN-CD19B, SGN-CD123A, SGN-352A, and ASG-15ME, as well as two immuno-oncology agents, SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology, and SGN-2FF, which is a small molecule. It also has multiple preclinical and research-stage programs that employ its technologies, including SGN-CD48A and a preclinical ADC. ADCETRIS is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent.

  Be the first to like this.


3286  2345  373  2965 

Top 10 Active Counters
 CELG 108.24+0.11 
 NIO 4.225-0.435 
 AVP 5.60-0.05 
 AABA 19.630.00 
 VIAB 24.22+0.75 
 ACHN 6.915+0.785 
 ECA 3.79-0.25 
 AMD 49.19-1.16 
 BBT 54.24+0.75 
 CHK 0.541-0.017 
Partners & Brokers